Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
Greipp
P T
PT
Kapoor
P
P
Morice
W G
WG
Witzig
T E
TE
Greipp
P R
PR
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab